These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 12628948

  • 1. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT).
    Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Val-HeFT Investigators.
    Circulation; 2003 Mar 11; 107(9):1278-83. PubMed ID: 12628948
    [Abstract] [Full Text] [Related]

  • 2. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
    Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN, Valsartan Heart Failure Trial Investigators.
    Circulation; 2002 Nov 05; 106(19):2454-8. PubMed ID: 12417542
    [Abstract] [Full Text] [Related]

  • 3. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, Cohn JN.
    Am Heart J; 2004 Dec 05; 148(6):951-7. PubMed ID: 15632877
    [Abstract] [Full Text] [Related]

  • 4. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN.
    Circ Heart Fail; 2008 May 05; 1(1):34-42. PubMed ID: 19808268
    [Abstract] [Full Text] [Related]

  • 5. C-reactive protein in heart failure: prognostic value and the effect of valsartan.
    Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, Val-HeFT Investigators.
    Circulation; 2005 Sep 06; 112(10):1428-34. PubMed ID: 16129801
    [Abstract] [Full Text] [Related]

  • 6. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN.
    Eur J Heart Fail; 2013 May 06; 15(5):511-8. PubMed ID: 23291728
    [Abstract] [Full Text] [Related]

  • 7. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure.
    Latini R, Masson S, Wong M, Barlera S, Carretta E, Staszewsky L, Vago T, Maggioni AP, Anand IS, Tan LB, Tognoni G, Cohn JN, Val-HeFT Investigators.
    Am J Med; 2006 Jan 06; 119(1):70.e23-30. PubMed ID: 16431191
    [Abstract] [Full Text] [Related]

  • 8. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cerè E, Tognoni G, Cohn JN, Val-HeFT Investigators.
    Am Heart J; 2005 Mar 06; 149(3):548-57. PubMed ID: 15864246
    [Abstract] [Full Text] [Related]

  • 9. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.
    Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN, Val-HeFT Investigators.
    Eur Heart J; 2004 Feb 06; 25(4):292-9. PubMed ID: 14984917
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial.
    Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN.
    Circ Heart Fail; 2014 May 06; 7(3):418-26. PubMed ID: 24622243
    [Abstract] [Full Text] [Related]

  • 11. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial.
    Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC.
    Circulation; 2010 Oct 05; 122(14):1387-95. PubMed ID: 20855664
    [Abstract] [Full Text] [Related]

  • 12. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure.
    Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M.
    Heart; 2006 May 05; 92(5):625-30. PubMed ID: 16159967
    [Abstract] [Full Text] [Related]

  • 13. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data.
    Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, Hester A, Anand I, Cohn JN.
    J Am Coll Cardiol; 2004 Jun 02; 43(11):2022-7. PubMed ID: 15172407
    [Abstract] [Full Text] [Related]

  • 14. Changes of plasma norepinephrine and serum N-terminal pro-brain natriuretic peptide after exercise training predict survival in patients with heart failure.
    Rengo G, Pagano G, Parisi V, Femminella GD, de Lucia C, Liccardo D, Cannavo A, Zincarelli C, Komici K, Paolillo S, Fusco F, Koch WJ, Perrone Filardi P, Ferrara N, Leosco D.
    Int J Cardiol; 2014 Feb 15; 171(3):384-9. PubMed ID: 24388546
    [Abstract] [Full Text] [Related]

  • 15. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
    Richards AM, Doughty R, Nicholls MG, Macmahon S, Ikram H, Sharpe N, Espiner EA, Frampton C, Yandle TG.
    Circulation; 1999 Feb 16; 99(6):786-92. PubMed ID: 9989964
    [Abstract] [Full Text] [Related]

  • 16. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 17. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
    Skvortsov AA, Mareev VIu, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Masenko VP, Belenkov IuN.
    Ter Arkh; 2006 Oct 20; 78(8):14-20. PubMed ID: 17078211
    [Abstract] [Full Text] [Related]

  • 18. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
    Skvortsov AA, Mareev VIu, Nasonova SN, Sychev AV, Arbolishvili GN, Baklanova NA, Masenko VP, Belenkov IuN.
    Ter Arkh; 2006 Oct 20; 78(9):61-71. PubMed ID: 17076227
    [Abstract] [Full Text] [Related]

  • 19. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
    Tan LB, Schlosshan D, Williams SG.
    Int J Clin Pract; 2004 Feb 20; 58(2):184-91. PubMed ID: 15055867
    [Abstract] [Full Text] [Related]

  • 20. Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure.
    Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD.
    J Am Coll Cardiol; 2016 Dec 06; 68(22):2425-2436. PubMed ID: 27908347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.